CureVac N.V. ( CVAC) Stock. Should you Buy or Sell? $ 9.68
0.00 (0.00 %)
CureVac N.V. AnalysisUpdated on 10-09-2022
|Volume Avg.||$528.82 thousand|
|Market Cap||$1.81 B|
|52 Week Range||$9.35 - $67.96|
CureVac N.V. opened the day at $9.68 which is 0.00 % on yesterday's close. CureVac N.V. has a 52 week high of $67.96 and 52 week low of $9.35, which is a difference of $58.61. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.81 B and total net profit is $102990000 which means the company is trading at 17.62 times profit to market capitalization. Theoretically, if you were to buy CureVac N.V. for $1.81 B, it would take 15 years to get your money back. CureVac N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
CureVac N.V. Stock Forecast - Is CureVac N.V. a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||-1.900|
Valuing CureVac N.V.
|Price Book Value Ratio||2.430||Price To Book Ratio||2.430|
|Price To Sales Ratio||13.161||Price Earnings Ratio||-6.928|
How liquid is CureVac N.V.
|Debt Ratio||0.327||Debt Equity Ratio||0.486|
|Long Term Debt To Capitalization||0.055||Total Debt To Capitalization||0.061|
Latest news about CureVac N.V.
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.
CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.
CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.
About CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.